Cure Alzheimer’s Fund presents: TAKING CONTROL OF ALZHEIMER’S THROUGH RESEARCH Thank you to all who attended our Symposium on Oct. 18 in Boston. Below are questions and answers that were submitted that day. Presenters MODERATOR Robert Bazell, Chief Science & Health Correspondent, NBC News PANEL Rudolph Tanzi, Ph.D., Harvard Medical School/Massachusetts General Hospital; Chairman, CureAlz Research Consortium Robert Moir, ...
August 12, 2011
***** On January 31, 2024, in a press release, Biogen announced that it is discontinuing production of Aduhelm. From the release, “The company will discontinue the development and commercialization of ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use and will terminate the ENVISION clinical study.” ***** On April 7, 2022, the ...
May 3, 2022
The Four Known Alzheimer’s Genes Over the past several decades, it has become increasingly clear that inheritance plays a major role in Alzheimer’s disease. The roughly 25,000 genes in the human genome are comprised of deoxyribonucleic acid (DNA) packaged into 24 different chromosomes, 1-22, X and Y. A gene’s job is ...
April 18, 2011
Cure Alzheimer’s Fund presented a webinar, Two Sides of Abeta for the Layperson, on Wednesday, Jan. 25, 2012. The presentation, moderated by David Shenk, author of the national bestseller The Forgetting, Alzheimer’s: Portrait of an Epidemic, featured Dr. Rudy Tanzi and Dr. Rob Moir. These Alzheimer’s experts looked at Abeta and ...
January 25, 2012
Prepared by: Rudolph E. Tanzi, Ph.D. Chairperson, Cure Alzheimer’s Fund Research Consortium Joseph P. and Rose F. Kennedy Professor of Neurology Harvard Medical School, Director, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease Department of Neurology Massachusetts General Hospital 114 16th Street Charletown, MA [email protected] Timothy W. Armour President and CEO Cure Alzheimer’s Fund 34 Washington Street Suite 300 Wellesly Hills, MA [email protected] The ...
August 20, 2009
SUMMARY After declaring aducanumab a failure, new data from Biogen’s clinical trial suggests the drug may help slow cognitive decline in some patients. In the EMERGE trial for aducanumab, patients receiving the highest dose saw 23% less cognitive decline on the Clinical Dementia Rating-Sum of Boxes test in comparison to patients receiving ...
October 30, 2019
Are you a Boston Globe subscriber? If so, we ask you to support Cure Alzheimer’s Fund through the brand new GRANT program (Globe Readers And Non-profits Together). Using this program, you can help us to gain free advertising space in the Globe newspaper at no cost to you. GRANT gives every ...
February 4, 2014
Cure Alzheimer’s Fund’s Dr. Rudy Tanzi’s submitted answers to Senator Hillary Rodham Clinton’s questions from the May 14, 2008, Senate Special Committee on Aging “The Future of Alzheimer’s: Breakthroughs and Challenges” Questions How can we best identify those at risk for Alzheimer’s Disease? Are there effective new drugs coming out anytime soon? How critical ...
June 8, 2008
Largest Single Private Investment in Alzheimer’s Whole Genome Sequencing Targets Effective Therapies and Cure: $5.4 Million Awarded for Research to Guide Alzheimer’s Drug Development Understanding who is most susceptible to Alzheimer’s disease and developing early detection models, effective therapies and possibly a cure, is the goal of the largest single private ...
October 18, 2012
A new blood test, which has the potential to accurately diagnose Alzheimer’s disease in individuals and significantly advance drug testing and research on the disease, has been developed through grant funding by Cure Alzheimer’s Fund. The test, known as Immunosignature (IS) and developed by a team led by UCLA neurologist Lucas ...
April 28, 2014
